Table 1.

Yale neoadjuvant cohort characteristics

Characteristicn (%)
Age (y)
 <5055 (58.5)
 ≥5039 (41.5)
 Unknown0 (0)
Nodal status
 Positive48 (51.1)
 Negative32 (34.0)
 Unknown14 (14.9)
Tumor size (cm)
 <210 (10.6)
 >283 (88.3)
 Unknown1 (1.1)
Nuclear grade
 1–248 (51.1)
 343 (45.7)
 Unknown3 (3.2)
Estrogen receptor
 Negative35 (37.2)
 Positive57 (60.7)
 Unknown2 (2.1)
Progesterone receptor
 Negative42 (44.7)
 Positive50 (53.2)
 Unknown2 (2.1)
HER2
 Negative68 (72.3)
 Positive25 (26.6)
 Unknown1 (1.1)
Triple-negative
 Yes23 (24.4)
 No70 (74.5)
 Unknown1 (1.1)
LPBC
 Yes8 (8.5)
 No84 (89.4)
 Unknown2 (2.1)
Treatment
 Adriamycin-based72 (76.6)
 Carboplatin + taxane + trastuzumab10 (10.6)
 Carboplatin + (nab)-paclitaxel + bevacizumab6 (6.4)
 Carboplatin + (nab)-paclitaxel + trastuzumab3 (3.2)
 Carboplatin + paclitaxel + etoposide1 (1.1)
 Cyclophosphamide + docetaxel2 (2.1)

Abbreviation: LBPC, lipocyte-predominant breast cancer.